

Rick Geoffrion has been appointed an Independent Board Director in Approxima to support advancement of a percutaneous right ventricular reshaping technology to treat patients with tricuspid valve regurgitation.

Milan, Italy, June 3, 2025 – **Approxima Srl** announced today the **appointment** of **Rick Geoffrion**, seasoned MedTech entrepreneur as an **independent Board Director**.

Rick Geoffrion has more than 35 years of management experience in the medical device industry and more specifically in the cardiovascular device space. Mr. Geoffrion has previously led the company foundation for four medical device companies: Mitralign (acquired by Edwards), CircuLite (acquired by HeartWare), FlowMedica (acquired by Angiodynamics) and X-Cell and guided the recapitalization and redirection of two other successful medical device companies: Impella (acquired by Abiomed) and Pathway (acquired by Bayer). Mr. Geoffrion has served as the Chairman of Impella CardioSystems, Circulite, FlowMedica, Aventamed (acquired by Storz) and Corflow Therapeutics. .

Rick currently serves as the President and CEO of Cyrano Therapeutics, Vice Chairman of the Mullings Group and as a member of the Executive Committee and Board of Directors of the Medical Device Innovation Consortium..

Mr. Geoffrion joins Approxima at a pivotal moment, following the successful first closing of the company's Series A financing round (read more: [LINK](#)) and as it prepares to initiate pilot clinical trials of its percutaneous right ventricular reshaping technology for the treatment of tricuspid regurgitation.

"On behalf of the Board and the entire Company, I am pleased to welcome Rick Geoffrion to Approxima," said Umberto Pasquali, Chairman of the Board. "Rick's extensive experience in the MedTech sector will further strengthen our Board, supporting Approxima's mission of delivering a transformative medical technology to patients suffering from tricuspid regurgitation."

"We are excited to work closely with Rick Geoffrion as we embark on this next stage of growth," added Michal Jaworek, CEO and Co-founder of Approxima. "His strategic vision and proven leadership in the cardiovascular space will be instrumental as we advance the development and validation of our technology."

"Having spent a number of years in the Tricuspid Valve Repair space, I have come to appreciate the need for a device therapy that can not only be effective, but can be deployed in a simple and repeatable way. Approxima has the opportunity to be that type of therapy. I am honored to become a member of the Board. " stated Rick Geoffrion.

About Approxima

Approxima was founded in 2020 by biomedical engineers M. Jaworek, E. Maroncelli, R. Vismara, G.B. Fiore and F. Lucherini as a spin-off from Politecnico di Milano. Approxima aspires to provide a transformative therapeutic solution for patients with tricuspid valve regurgitation based on the approach of ventricular reshaping which can restore physiological functioning of the tricuspid valve. The device is intended to be implanted into the heart of a patient via totally percutaneous and straightforward beating-heart procedure. The company headquarter is located in Milan, Italy.

<https://www.approximamedical.com/>